Category: Uncategorized

BioLife today announced the launch of its new corporate brand identity, redesigned logo, and website. The new brand identity was created to better reflect BioLife’s expanded portfolio of bioproduction tools and services. Todd Berard, Chief Marketing Officer, remarked, “We pursued a refreshed design that appropriately positions BioLife as the premier supplier of cell and gene…

evo System Adopted by Leading Specialty Logistics Service Providers and Cell Therapy Manufacturers as Best Practice On May 2, 2018, our Joint Venture partner,  SAVSU Technologies, the leading developer of smart precision shipping containers and cloud-based cold chain management SaaS solutions, announced two major upgrades to its industry best evo system; including enhanced software and shipping…

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno- modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during biopreservation/stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe.…

Q4 2017 Preliminary Revenue Reaches Record $3.1 Million, up 39% over Q4 2016 On January 4, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary Q4 and full year 2017 revenue and provided additional operational updates and financial guidance for 2018.…

On December 13, 2017 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. (“Iovance”) (NASDAQ: IOVA). Iovance is…

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor – powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world’s first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions…